CannBioRx Life Financials
ATNFW Stock | USD 0.01 0.0008 8.89% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 0.87 | 0.83 |
|
|
Investors should never underestimate CannBioRx Life's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor CannBioRx Life's cash flow, debt, and profitability to make informed and accurate decisions about investing in CannBioRx Life Sciences.
Net Income |
|
CannBioRx | Select Account or Indicator |
Understanding current and past CannBioRx Life Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of CannBioRx Life's financial statements are interrelated, with each one affecting the others. For example, an increase in CannBioRx Life's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in CannBioRx Life's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of CannBioRx Life Sciences. Check CannBioRx Life's Beneish M Score to see the likelihood of CannBioRx Life's management manipulating its earnings.
CannBioRx Life Stock Summary
CannBioRx Life competes with 180 Life. CannBioRx Life Sciences Corp. discovers and develops pharmaceutical drugs. 180 Life is traded on NASDAQ Exchange in the United States.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
CUSIP | 48242A112 68236V112 |
Location | California; U.S.A |
Business Address | Building 4, Palo |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | 180lifesciences.com |
Phone | 650 507 0669 |
Currency | USD - US Dollar |
CannBioRx Life Key Financial Ratios
Return On Equity | -1.74 | ||||
EBITDA | (22.13 M) | ||||
Net Income | (19.94 M) | ||||
Book Value Per Share | 3.64 X | ||||
Market Capitalization | 250.78 M |
CannBioRx Life Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 55.5M | 62.7M | 19.7M | 5.3M | 4.7M | 4.5M | |
Retained Earnings | (48.4M) | (68.7M) | (107.4M) | (127.3M) | (114.6M) | (108.9M) | |
Total Liab | 25.2M | 23.4M | 8.3M | 5.4M | 6.2M | 11.6M | |
Total Current Assets | 4.0M | 11.2M | 8.9M | 3.6M | 4.2M | 4.0M | |
Short Term Debt | 3.7M | 1.9M | 1.3M | 1.0M | 930.7K | 1.5M | |
Common Stock | 2.6K | 3.4K | 375.0 | 54.0 | 48.6 | 46.17 | |
Other Current Liab | 9.2M | 17.2M | 2.5M | 2.1M | 2.5M | 2.3M | |
Net Debt | 1.7M | (6.3M) | (5.6M) | (921.7K) | (829.6K) | (871.0K) | |
Cash | 2.1M | 8.2M | 7.0M | 2.0M | 2.3M | 3.2M | |
Accounts Payable | 8.5M | 586.6K | 1.8M | 1.9M | 1.7M | 2.7M | |
Net Receivables | 784.6K | 694.6K | 621.0K | 279.0K | 251.1K | 433.2K | |
Other Current Assets | 1.1M | 3.0M | 1.3M | 1.7M | 1.9M | 1.6M | |
Net Invested Capital | 34.1M | 41.3M | 12.7M | 926.3K | 833.7K | 792.0K | |
Short Long Term Debt | 3.7M | 1.9M | 1.3M | 1.0M | 930.7K | 1.8M | |
Capital Stock | 2.6K | 3.4K | 375.0 | 54.0 | 48.6 | 46.17 | |
Net Working Capital | (17.4M) | (8.5M) | 3.3M | (1.4M) | (1.6M) | (1.7M) | |
Intangible Assets | 14.6M | 14.5M | 10.7M | 1.6M | 1.5M | 1.4M |
CannBioRx Life Key Income Statement Accounts
The reason investors look at the income statement is to determine what CannBioRx Life's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Interest Expense | 1.1M | 186.2K | 26.7K | 44.83 | 51.55 | 48.98 | |
Operating Income | (5.6M) | (15.6M) | (17.9M) | (13.5M) | (12.1M) | (12.7M) | |
Income Before Tax | (10.9M) | (20.3M) | (39.7M) | (22.3M) | (20.1M) | (21.1M) | |
Net Income | (10.9M) | (20.3M) | (38.7M) | (19.9M) | (17.9M) | (18.8M) | |
Tax Provision | (20.4K) | (23.2K) | (942.7K) | (3.3M) | (3.0M) | (2.8M) | |
Ebit | (9.8M) | (20.2M) | (17.9M) | (22.2M) | (20.0M) | (21.0M) | |
Ebitda | (9.7M) | (20.0M) | (17.8M) | (22.1M) | (19.9M) | (20.9M) | |
Income Tax Expense | (20.4K) | 23.2K | 942.7K | (2.3M) | (2.1M) | (2.0M) | |
Research Development | 2.3M | 3.9M | 2.4M | 2.8M | 3.2M | 2.7M | |
Net Interest Income | (1.1M) | (186.2K) | (26.7K) | (40.8K) | (47.0K) | (49.3K) |
CannBioRx Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CannBioRx Life's current stock value. Our valuation model uses many indicators to compare CannBioRx Life value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CannBioRx Life competition to find correlations between indicators driving CannBioRx Life's intrinsic value. More Info.CannBioRx Life Sciences is rated third in return on equity category among its peers. It also is rated third in return on asset category among its peers . At this time, CannBioRx Life's Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value CannBioRx Life by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.CannBioRx Life Sciences Systematic Risk
CannBioRx Life's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. CannBioRx Life volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on CannBioRx Life Sciences correlated with the market. If Beta is less than 0 CannBioRx Life generally moves in the opposite direction as compared to the market. If CannBioRx Life Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one CannBioRx Life Sciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of CannBioRx Life is generally in the same direction as the market. If Beta > 1 CannBioRx Life moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as CannBioRx Life is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of CannBioRx has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if CannBioRx Life's financials are consistent with your investment objective using the following steps:- Review CannBioRx Life's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand CannBioRx Life's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare CannBioRx Life's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if CannBioRx Life's stock is overvalued or undervalued.
Today, most investors in CannBioRx Life Stock are looking for potential investment opportunities by analyzing not only static indicators but also various CannBioRx Life's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of CannBioRx Life growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
CannBioRx Life March 25, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of CannBioRx Life help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of CannBioRx Life Sciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of CannBioRx Life Sciences based on widely used predictive technical indicators. In general, we focus on analyzing CannBioRx Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build CannBioRx Life's daily price indicators and compare them against related drivers.
Downside Deviation | 10.52 | |||
Information Ratio | 0.0598 | |||
Maximum Drawdown | 133.33 | |||
Value At Risk | (12.62) | |||
Potential Upside | 13.0 |
Additional Tools for CannBioRx Stock Analysis
When running CannBioRx Life's price analysis, check to measure CannBioRx Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CannBioRx Life is operating at the current time. Most of CannBioRx Life's value examination focuses on studying past and present price action to predict the probability of CannBioRx Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CannBioRx Life's price. Additionally, you may evaluate how the addition of CannBioRx Life to your portfolios can decrease your overall portfolio volatility.